









Markets
/
Stocks
/
nasdaq-tngx
/

Tango Therapeutics Inc

TNGX

7.840USD

-0.170-2.12%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

869.23MMarket Cap

LossP/E TTM



Tango Therapeutics Inc

7.840

-0.170-2.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tango Therapeutics Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tango Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

68 / 407

Overall Ranking

173 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

12.125

Target Price

+49.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tango Therapeutics Inc Highlights

StrengthsRisks

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 69.22% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 42.07M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 42.07M.

Fairly Valued

The company’s latest PE is -6.06, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 122.99M shares, increasing 2.09% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.59K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.25.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 5.75, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 3.18M, representing a year-over-year decrease of 83.99%, while its net profit experienced a year-over-year decrease of 52.06%.

Score

Industry at a Glance

Previous score

5.75

Change



Financials

5.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.93

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Tango Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.19, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -6.06, which is -84.93% below the recent high of -0.91 and -97.53% above the recent low of -11.97.

Score

Industry at a Glance

Previous score

6.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.89, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Tango Therapeutics Inc is 12.50, with a high of 15.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

12.125

Target Price

+49.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Tango Therapeutics Inc

TNGX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 7.34, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 9.58 and the support level at 6.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.30

Change

0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.183

Neutral

RSI(14)

50.394

Neutral

STOCH(KDJ)(9,3,3)

48.447

Neutral

ATR(14)

0.700

Low Volatility

CCI(14)

-46.453

Neutral

Williams %R

56.146

Sell

TRIX(12,20)

0.164

Sell

StochRSI(14)

65.915

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

7.942

Sell

MA10

8.016

Sell

MA20

8.143

Sell

MA50

7.626

Buy

MA100

6.870

Buy

MA200

4.488

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 94.17%, representing a quarter-over-quarter decrease of 12.67%. The largest institutional shareholder is The Vanguard, holding a total of 4.03M shares, representing 3.01% of shares outstanding, with 18.54% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Third Rock Ventures, LLC

14.06M

-10.18%

TCG Crossover Management, LLC

10.74M

EcoR1 Capital, LLC

10.63M

Boxer Capital Management, LLC

9.77M

-5.87%

Farallon Capital Management, L.L.C.

9.16M

+98.59%

Woodline Partners LP

6.03M

+1091.24%

Adage Capital Management, L.P.

5.91M

Invus Public Equities Advisors, LLC

5.88M

+74.84%

Nextech Invest, Ltd.

5.53M

BlackRock Institutional Trust Company, N.A.

4.95M

+32.30%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 4.65, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.67. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.